An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy.

Trial Profile

An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Dec 2009 Patient numbers amended from 93 to 78 as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Actual patient number (93) added as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top